Condition: Ovarian Cancer · Sponsor: Tubulis GmbH
The goal of this clinical study is to learn more about the safety, tolerability, and preliminary effectiveness of TUB-040 when given in combination with standard ovarian cancer treatments in participants with high-grade epithelial serous or endometrioid ovarian cancer. This study will also evaluate the appropriate dose of TUB-040 when used with carboplatin (Carbo) and bevacizumab (BEV), including determining the maximum tolerated dose (MTD) in participants with platinum-sensitive ovarian cancer.
This description comes directly from the study's public registry record.
Tubulis Clinical Trial Inquiries · + 49 175 800 5594 · ct-inquiries@tubulis.com
Always discuss trial participation with your own doctor first.
| UCL Louvain | Brussels, Belgium | Recruiting |
| UZ Gent | Ghent, Belgium | Recruiting |
| UZ Leuven | Leuven, Belgium | Recruiting |
| CHU de Liege | Liège, Belgium | Recruiting |
| ARENSIA Exploratory Medicine | Kyiv, Ukraine | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07736937